SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer

Pancreatic cancer is characterized by a poor prognosis, with its five-year survival rate lower than that of any other cancer type. Gemcitabine, a standard treatment for pancreatic cancer, often has poor outcomes for patients as a result of chemoresistance. Therefore, novel therapeutic targets must b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Myeong Jin, Kim, Hyung Sun, Kang, Hyeon Woong, Lee, Da Eun, Hong, Woosol Chris, Kim, Ju Hyun, Kim, Minsoo, Cheong, Jae-Ho, Kim, Hyo Jung, Park, Joon Seong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605569/
https://www.ncbi.nlm.nih.gov/pubmed/37887353
http://dx.doi.org/10.3390/cells12202509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605569/
https://www.ncbi.nlm.nih.gov/pubmed/37887353
http://dx.doi.org/10.3390/cells12202509

Ejemplares similares